Effects of metformin on weight loss: potential mechanisms
Wegovy is administered as a once-weekly subcutaneous (under the skin) self-injection with a typical dose of 2.4 mg for weight loss
The types of cancers reported were diverse and consistent with background rates expected in populations with type 2 diabetes and obesity, which themselves carry elevated baseline cancer risk
10.3109/00207454.2013.765419 10 BussoneG.CerboR.MartucciN.MicieliG.ZanferrariC.GrazziL.et al (1999)
The growing use of GLP-1 receptor agonists may affect cancer patients care because the drugs can influence results from FDG PET-CT scans, according to new research presented this week at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM25)
Diabetes, 38, 11651174 Crosignani, P.G., Colombo, M., Vegetti, W